Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 196063, 13 pages
http://dx.doi.org/10.1155/2012/196063
Review Article

Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes

1Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio 4, 00165 Rome, Italy
2Catholic University Medical School, 00168 Rome, Italy
3University of Pavia, 27100 Pavia, Italy

Received 30 October 2011; Revised 12 January 2012; Accepted 29 January 2012

Academic Editor: Arnon Nagler

Copyright © 2012 Sergio Rutella and Franco Locatelli. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [27 citations]

The following is the list of published articles that have cited the current article.

  • Yuefei Yu, Marjorie Jenkins, Everardo Cobos, Leonardo Mirandola, Constance M. John, and Maurizio Chiriva-Internati, “Targeting Galectin-3 unveils the complexity of multiple myeloma: A sweet context,” ACS Symposium Series, vol. 1115, pp. 289–307, 2012. View at Publisher · View at Google Scholar
  • Sébastien Viel, Emily Charrier, Antoine Marçais, Paul Rouzaire, Jacques Bienvenu, Lionel Karlin, Gilles Salles, and Thierry Walzer, “Monitoring NK cell activity in patients with hematological malignancies,” OncoImmunology, vol. 2, no. 9, pp. e26011, 2013. View at Publisher · View at Google Scholar
  • Suxin Zhang, Ke Yin, Yuqin Duan, Yanping Chen, Lantao Guo, Tianke Li, and Zhong Chen, “Expression and interaction of secretory immunoglobulin A, interleukin 6, and dendritic cells in oral cancers,” Chinese Journal of Clinical Oncology, vol. 40, no. 5, pp. 257–260, 2013. View at Publisher · View at Google Scholar
  • D Atanackovic, T Luetkens, and N Kröger, “Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma,” Leukemia, 2013. View at Publisher · View at Google Scholar
  • Lei Wang, Nan Jin, Anita Schmitt, Jochen Greiner, Georg Malcherek, Michael Hundemer, Jiju Mani, Dirk Hose, Marc S Raab, Anthony D. Ho, Bao-an Chen, Hartmut Goldschmidt, and Michael Schmitt, “T cell-based targeted immunotherapies for patients with multiple myeloma,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  • J Bae, R Prabhala, A Voskertchian, A Brown, C Maguire, P Richardson, G Dranoff, K C Anderson, and N C Munshi, “A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients,” Leukemia, 2014. View at Publisher · View at Google Scholar
  • Kenneth C. Anderson, and Giovanni Tononpp. 455–e4, 2014. View at Publisher · View at Google Scholar
  • Jacalyn Rosenblatt, Michal Bar-Natan, Nikhil C Munshi, and David E Avigan, “Immunotherapy for multiple myeloma,” Expert Review of Hematology, vol. 7, no. 1, pp. 91–96, 2014. View at Publisher · View at Google Scholar
  • Kim De Veirman, Els Van Valckenborgh, Qods Lahmar, Xenia Geeraerts, Elke De Bruyne, Eline Menu, Ivan Van Riet, Karin Vanderkerken, and Jo A. Van Ginderachter, “Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies,” Frontiers in Oncology, vol. 4, 2014. View at Publisher · View at Google Scholar
  • Rebecca Karp Leaf, Hearn Jay Cho, and David Avigan, “Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies,” Current Hematologic Malignancy Reports, 2015. View at Publisher · View at Google Scholar
  • Antonio Palumbo, and Pieter Sonneveld, “Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma,” Expert Review of Hematology, pp. 1–11, 2015. View at Publisher · View at Google Scholar
  • Ayed O. Ayed, Lung-Ji Chang, and Jan S. Moreb, “Immunotherapy for multiple myeloma: Current status and future directions,” Critical Reviews in Oncology/Hematology, 2015. View at Publisher · View at Google Scholar
  • Soudeh Ghafouri-Frad, Mahnaz Seifi-Alan, Roshanak Shamsi, and Ali Esfandiary, “Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens,” Iranian Journal of Cancer Prevention, vol. 8, no. 5, 2015. View at Publisher · View at Google Scholar
  • Sebastian Grosicki, and Agnieszka Barchnicka, “Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma,” Expert Review of Hematology, pp. 1–8, 2016. View at Publisher · View at Google Scholar
  • Andinet Alemu, John O. Richards, Martin K. Oaks, and Michael A. Thompson, “Vaccination in Multiple Myeloma: Review of Current Literature,” Clinical Lymphoma Myeloma and Leukemia, 2016. View at Publisher · View at Google Scholar
  • Ehsan Malek, Marcos de Lima, John J. Letterio, Byung-Gyu Kim, James H. Finke, James J. Driscoll, and Sergio A. Giralt, “Myeloid-derived Suppressor Cells: The Green Light for Myeloma Immune Escape,” Blood Reviews, 2016. View at Publisher · View at Google Scholar
  • Arnold Bolomsky, Martin Schreder, Wolfgang Hübl, Niklas Zojer, Wolfgang Hilbe, and Heinz Ludwig, “Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma,” Leukemia & Lymphoma, pp. 1–10, 2016. View at Publisher · View at Google Scholar
  • Sagar Lonial, Paola Neri, and Nizar J. Bahlis, “New strategies in multiple myeloma: Immunotherapy as a novel approach to treat patients with multiple myeloma,” Clinical Cancer Research, vol. 22, no. 24, pp. 5959–5965, 2016. View at Publisher · View at Google Scholar
  • Silvio Buffa, Calogero Caruso, Fanny Pojero, Alessandra Casuccio, Caterina Giambanco, Matteo Bulati, Francesco Di Bassiano, Francesco Gervasi, and Giuseppina Colonna Romano, “Bone marrow B lymphocytes in multiple myeloma and MGUS: Focus on distribution of naïve cells and memory subsets,” Leukemia Research, vol. 49, pp. 51–59, 2016. View at Publisher · View at Google Scholar
  • Matthew J. Pianko, Yuzhou Liu, Srishti Bagchi, and Alexander M. Lesokhin, “Immune checkpoint blockade for hematologic malignancies: A review,” Stem Cell Investigation, vol. 2017, 2017. View at Publisher · View at Google Scholar
  • Xin Zhang, Yin, Zhong Chen, Suxin Zhang, Tianke Li, and Yang Bao, “Variation and significance of secretory immunoglobulin A, interleukin 6 and dendritic cells in oral cancer,” Oncology Letters, vol. 13, no. 4, pp. 2297–2303, 2017. View at Publisher · View at Google Scholar
  • J Bae, T Hideshima, G L Zhang, J Zhou, D B Keskin, N C Munshi, and K C Anderson, “Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma,” Leukemia, 2017. View at Publisher · View at Google Scholar
  • Jean-Samuel Boudreault, Cyrille Touzeau, and Philippe Moreau, “The role of SLAMF7 in multiple myeloma: impact on therapy,” Expert Review of Clinical Immunology, vol. 13, no. 1, pp. 67–75, 2017. View at Publisher · View at Google Scholar
  • Donatella D'Eliseo, Livia Di Renzo, Angela Santoni, and Francesca Velotti, “Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells.,” Genes & cancer, vol. 8, no. 1-2, pp. 426–437, 2017. View at Publisher · View at Google Scholar
  • Massimo Giuliani, Bassam Janji, and Guy Berchem, “Activation of NK cells and disruption of PD-L1/PD-1 axis: Two different ways for lenalidomide to block myeloma progression,” Oncotarget, vol. 8, no. 14, pp. 24031–24044, 2017. View at Publisher · View at Google Scholar
  • Rebecca Karp Leaf, Dina Stroopinsky, Athalia R. Pyzer, Ada M. Kruisbeek, Sandra van Wetering, Abigail Washington, Adam Ephraim, Leandra Cole, Adam Morin, Salvia Jain, Myrna R. Nahas, Arik Apel, Jon Arnason, Ayad Hamdan, Jacalyn Rosenblatt, and David Avigan, “DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma,” Journal of Immunotherapy, vol. 40, no. 9, pp. 315–322, 2017. View at Publisher · View at Google Scholar
  • Lien De Beck, Sarah Melhaoui, Kim De Veirman, Eline Menu, Elke De Bruyne, Karin Vanderkerken, Karine Breckpot, and Ken Maes, “Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects,” OncoImmunology, 2018. View at Publisher · View at Google Scholar